DC Journal ran an op-ed penned by ERIC President and CEO James Gelfand where he sets forth the need for Congress to eliminate switching studies that delay interchangeability with regards to biosimilar approvals. In his op-ed, he endorsed S.1954, the “Biosimilar Red Tape Elimination Act,” introduced by Sens. Mike Lee (R-UT) and Ben Ray Luján (D-NM), which eliminates those studies, which he argues “serve no purpose other than delaying Americans’ access to lower-cost biosimilar alternatives.
The FTC and DOJ held a public “listening session” on June 30, 2025, to gather expert testimony on anticompetitive pharmaceutical practices, with ERIC’s CEO James Gelfand highlighting how employer-sponsored plans are burdened by inflated drug prices and opaque PBM tactics — such as hiding pricing data and steering patients toward more expensive brand-name medications — while experts also shed light on patent abuses and “pay-for-delay” schemes that suppress generic and biosimilar competition
This blog calls for pharmacy benefit manager (PBM) reforms and comprehensive policy solutions to reduce drug costs and increase competition to allow for more generics and biosimilars to come to market.
